AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS for AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Waste (hazardous/solid/interstate/nuclear) WAS
Communication to Environmental Protection Agency regarding addition of pharmaceuticals to universal waste rule.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JUSTINE COFFEY | — |
| MORGAN HANSON | — |
| JOSEPH M HILL | — |
| BRIAN M MEYER | — |
| GERALYN TRUJILLO | — |
Health Issues HCR
HR 1, American Recovery and Reinvestment Act, Title XIII, Health information technology provisions. FDA appropriations FY09 & FY10. Communication re: confirmation of Secretary-Designate Daschle, and Sebelius. Communication to White House Office regarding health care reform. Statement to Senate Finance Committee on workforce and health care reform. Health care reform (no bill #). Letter to Office of the Nat. Coordinator for Health Information Technology regarding Standards Committee appointment.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JUSTINE COFFEY | — |
| MORGAN HANSON | — |
| JOSEPH M HILL | — |
| BRIAN M MEYER | — |
| GERALYN TRUJILLO | — |
Medicare/Medicaid MMM
Communication and meetings with CMS staff regarding compendia recognition. Presentation and written testimony before CMS Ambulatory Payment Classification Panel regarding pharmacy overhead. Communication to CMS re: nomination to APC panel. Comments to CMS re: 2010 call letter concerning Part D medication therapy management programs. Communication to CMS regarding payment policy for outpatient anticoagulation services.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JUSTINE COFFEY | — |
| MORGAN HANSON | — |
| JOSEPH M HILL | — |
| BRIAN M MEYER | — |
| GERALYN TRUJILLO | — |
Pharmacy PHA
Communication seeking withdrawal of propxyphene from the market. Communication re: experimental study of consumer reporting of side effects as part of direct-to-consumer advertising. Communication re: evaluation and usefulness of consumer medication information. Communication re: FDA's Sentinal Initiative to monitor medical product safety. Comments on disposal of controlled substances.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JUSTINE COFFEY | — |
| MORGAN HANSON | — |
| JOSEPH M HILL | — |
| BRIAN M MEYER | — |
| GERALYN TRUJILLO | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.